ValuEngine downgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a sell rating to a strong sell rating in a research report sent to investors on Friday morning.
LXRX has been the topic of a number of other reports. Zacks Investment Research downgraded shares of Lexicon Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, January 31st. BidaskClub upgraded shares of Lexicon Pharmaceuticals from a strong sell rating to a sell rating in a research report on Saturday, January 20th. Finally, Wedbush restated an outperform rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, October 5th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. Lexicon Pharmaceuticals currently has an average rating of Hold and a consensus target price of $28.50.
Lexicon Pharmaceuticals (NASDAQ LXRX) opened at $9.60 on Friday. The company has a current ratio of 1.66, a quick ratio of 1.65 and a debt-to-equity ratio of 1.09. Lexicon Pharmaceuticals has a 52-week low of $8.07 and a 52-week high of $18.00. The stock has a market cap of $1,031.06, a PE ratio of -7.75 and a beta of 0.24.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.07. Lexicon Pharmaceuticals had a negative net margin of 165.69% and a negative return on equity of 111.68%. The company had revenue of $26.94 million for the quarter, compared to the consensus estimate of $27.97 million. During the same period in the prior year, the company posted ($0.35) EPS. The company’s revenue was down 2.8% compared to the same quarter last year. equities research analysts anticipate that Lexicon Pharmaceuticals will post -1.38 earnings per share for the current year.
In other news, CEO Lonnel Coats purchased 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The shares were acquired at an average cost of $9.91 per share, for a total transaction of $99,100.00. Following the transaction, the chief executive officer now directly owns 42,985 shares of the company’s stock, valued at approximately $425,981.35. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Public Equities L.P. Invus purchased 575,946 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The stock was purchased at an average price of $9.64 per share, for a total transaction of $5,552,119.44. The disclosure for this purchase can be found here. Insiders purchased a total of 914,353 shares of company stock worth $8,916,253 over the last quarter. 5.77% of the stock is currently owned by corporate insiders.
Large investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. raised its position in shares of Lexicon Pharmaceuticals by 17.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 134,043 shares of the biopharmaceutical company’s stock valued at $2,205,000 after acquiring an additional 20,379 shares during the period. Kornitzer Capital Management Inc. KS acquired a new stake in shares of Lexicon Pharmaceuticals in the 3rd quarter valued at approximately $9,420,000. Ameriprise Financial Inc. acquired a new stake in shares of Lexicon Pharmaceuticals in the 2nd quarter valued at approximately $1,261,000. GSA Capital Partners LLP raised its position in shares of Lexicon Pharmaceuticals by 158.0% in the 3rd quarter. GSA Capital Partners LLP now owns 50,786 shares of the biopharmaceutical company’s stock valued at $624,000 after acquiring an additional 31,100 shares during the period. Finally, Wells Fargo & Company MN raised its position in shares of Lexicon Pharmaceuticals by 27.2% in the 3rd quarter. Wells Fargo & Company MN now owns 112,721 shares of the biopharmaceutical company’s stock valued at $1,385,000 after acquiring an additional 24,131 shares during the period.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.